There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enanta Pharmaceuticals (ENTA – Research Report), Spruce Biosciences (SPRB – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments.
Enanta Pharmaceuticals (ENTA)
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Enanta Pharmaceuticals on January 4 and set a price target of $40.00. The company’s shares closed last Monday at $12.41, close to its 52-week low of $8.08.
According to TipRanks.com, Skorney is a 1-star analyst with an average return of
Enanta Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $24.80, implying an 111.2% upside from current levels. In a report issued on January 5, H.C. Wainwright also maintained a Buy rating on the stock with a $28.00 price target.
See today’s best-performing stocks on TipRanks >>
Spruce Biosciences (SPRB)
In a report issued on January 4, Joseph Schwartz from Leerink Partners maintained a Buy rating on Spruce Biosciences. The company’s shares closed last Monday at $2.80.
According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Spruce Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.67, a 194.9% upside from current levels. In a report issued on January 5, JMP Securities also reiterated a Buy rating on the stock with a $8.00 price target.
Axsome Therapeutics (AXSM)
In a report issued on January 5, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Axsome Therapeutics, with a price target of $90.00. The company’s shares closed last Monday at $88.94, close to its 52-week high of $91.29.
According to TipRanks.com, Suvannavejh is a 1-star analyst with an average return of
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $119.29, a 42.5% upside from current levels. In a report issued on December 26, H.C. Wainwright also reiterated a Buy rating on the stock with a $180.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ENTA:
